| Theme | NASH 2018 | |
|---|---|---|
| Title | Pharmacotherapy for Liver Fibrosis in NASH Patients | |
| Publish Date | 2018/01 | |
| Author | Takemi Akahane | Third Department of Internal Medicine, Nara Medical University |
| Author | Hitoshi Yoshiji | Third Department of Internal Medicine, Nara Medical University |
| [ Summary ] | Liver fibrosis is the most important predictor of mortality among nonalcoholic steatohepatitis (NASH) patients. The risk of liver‒related mortality increases exponentially with an increase in the stage of fibrosis. Recent studies have revealed that liver fibrosis is reversible and the mechanisms of fibrosis progression in NASH patients are being elucidated. Therefore, several ongoing clinical trials are focused on antifibrotic therapy to improve prognosis in NASH patients. Various factors are involved in the progression of liver fibrosis ; therefore, combination therapy targeting different aspects of the pathogenesis may be the most effective strategy to improve liver outcomes. Personalized medicine using the most effective combination therapy based on each patient's needs likely represents the best future direction. | |